Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

Researchers randomly assigned patients 30 to 70 years of age with BCR::ABL1-negative BCP-ALL who had MRD-negative remission after induction and intensification chemotherapy to receive four cycles of blinatumomab in addition to four cycles of consolidation chemotherapy or to receive four cycles of consolidation chemotherapy alone.